menu
    • menu
    [{"orgOrder":0,"company":"Tolerance Bio","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"iPSC-based cell therapy","moa":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Tolerance Bio","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"","sponsorNew":"Tolerance Bio \/ Columbus Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Tolerance Bio \/ Columbus Venture Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by Tolerance Bio

    Menu

    Tolerance Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tolerance Bio

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Tolerance Bio

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Pacific 8 Ventures

                            Deal Size : $20.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Tolerance Bio Completes $20.2M Seed Round to Advance Thymus-Based Therapies

                            Details : The funding will enable the company to develop induced pluripotent stem cell (iPSC)-based thymus cells and pharmacological thymus therapies to treat immune-mediated diseases.

                            Product Name : Undisclosed

                            Product Type :

                            Upfront Cash : Undisclosed

                            December 19, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Pacific 8 Ventures

                            Deal Size : $20.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tolerance Bio

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Tolerance Bio

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iPSC-based cell therapy

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Columbus Venture Partners

                            Deal Size : $17.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Tolerance Bio Launches with $17.2M to Advance Thymus-Based Immune Therapies

                            Details : The proceeds from the financing will be used to advance thymus-based therapies for immune-mediated diseases.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 15, 2024

                            Lead Product(s) : iPSC-based cell therapy

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Columbus Venture Partners

                            Deal Size : $17.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth